Agency Information Collection Activities: Proposed Collection: Public Comment Request, 76309-76310 [2013-29991]
Download as PDF
wreier-aviles on DSK5TPTVN1PROD with NOTICES
Federal Register / Vol. 78, No. 242 / Tuesday, December 17, 2013 / Notices
(Rm. 1503), Silver Spring, MD 20993–
0002. Information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/default.htm; under
the heading ‘‘Resources for You,’’ click
on ‘‘Public Meetings at the FDA White
Oak Campus.’’ Please note that visitors
to the White Oak Campus must enter
through Building 1.
Contact Person: Kristina Toliver,
Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 31, Rm. 2417, Silver Spring,
MD 20993–0002, 301–796–9001, FAX:
301–847–8533, email: CRDAC@
fda.hhs.gov, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
Agenda: The committee will discuss
new drug application (NDA) 203202,
NORTHERA (droxidopa capsules),
submitted by Chelsea Therapeutics, Inc.,
for the treatment of symptomatic
neurogenic orthostatic hypotension in
patients with primary autonomic failure
(Parkinson’s disease, multiple system
atrophy, or pure autonomic failure),
dopamine beta-hydroxylase deficiency,
and non-diabetic autonomic
neuropathy.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
VerDate Mar<15>2010
14:45 Dec 16, 2013
Jkt 232001
person on or before January 9, 2014.
Oral presentations from the public will
be scheduled between approximately 1
p.m. and 2 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before January
3, 2014. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by January 6, 2014.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Kristina
Toliver at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: December 11, 2013.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2013–29917 Filed 12–16–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Proposed Collection: Public
Comment Request
Health Resources and Services
Administration, HHS.
AGENCY:
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
ACTION:
76309
Notice.
In compliance with the
requirement for opportunity for public
comment on proposed data collection
projects (Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995), the
Health Resources and Services
Administration (HRSA) announces
plans to submit an Information
Collection Request (ICR), described
below, to the Office of Management and
Budget (OMB). Prior to submitting the
ICR to OMB, HRSA seeks comments
from the public regarding the burden
estimate, below, or any other aspect of
the ICR.
DATES: Comments on this Information
Collection Request must be received
within 60 days of this notice.
ADDRESSES: Submit your comments to
paperwork@hrsa.gov or mail the HRSA
Information Collection Clearance
Officer, Room 10–29, Parklawn
Building, 5600 Fishers Lane, Rockville,
MD 20857.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and draft
instruments, email paperwork@hrsa.gov
or call the HRSA Information Collection
Clearance Officer at (301) 443–1984.
SUPPLEMENTARY INFORMATION: When
submitting comments or requesting
information, please include the
information request collection title for
reference.
Information Collection Request Title:
HRSA AIDS Drug Assistance Program
Quarterly Report OMB No. 0915–0294—
Extension
Abstract: HRSA’s AIDS Drug
Assistance Program (ADAP) is funded
through Part B of Title XXVI of the
Public Health Service Act, as amended
by the Ryan White HIV/AIDS Treatment
Extension Act of 2009 (The Ryan White
HIV/AIDS Program), which provides
grants to states and territories. ADAP
provides medications for the treatment
of HIV disease. Program funds may also
be used to purchase health insurance for
eligible clients or for services that
enhance access, adherence, and
monitoring of drug treatments.
Need and Proposed Use of the
Information: Each of the 50 states, the
District of Columbia, Puerto Rico, the
Virgin Islands, and the Pacific territories
receive ADAP grants. As part of the
funding requirements, ADAP grantees
submit quarterly reports that include
information on patients served,
pharmaceuticals dispensed, pricing,
sources of support to provide HIV/AIDS
medications, eligibility requirements,
cost data, and coordination with
SUMMARY:
E:\FR\FM\17DEN1.SGM
17DEN1
76310
Federal Register / Vol. 78, No. 242 / Tuesday, December 17, 2013 / Notices
Medicaid. Each quarterly report requests
updates from programs on the number
of patients served, type of
pharmaceuticals dispensed, and prices
paid to provide medications. The first
quarterly report of each ADAP fiscal
year (due in July of each year) also
requests information that only changes
annually (e.g., state funding, drug
formulary, eligibility criteria for
enrollment, and cost-saving strategies
including coordination with Medicaid).
Describe the need for the information
and proposed use of the information:
The quarterly report represents the best
method for HRSA to determine how
ADAP grant funds are expended and to
provide answers to requests from
Congress and other organizations.
Likely Respondents: ADAP Grantees.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install and utilize
technology and systems for the purpose
of collecting, validating and verifying
information, processing and
Number of
respondents
Form name
ADAP Quarterly Report—Qtr. 1 ...........................................
ADAP Quarterly Reports—Qtr. 1, 2, & 3 .............................
Total ..............................................................................
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions, (2) the accuracy of the
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
Dated: December 9, 2013.
Bahar Niakan,
Director, Division of Policy and Information
Coordination.
[FR Doc. 2013–29991 Filed 12–16–13; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Submission to OMB for
Review and Approval; Public Comment
Request
Health Resources and Services
Administration, HHS.
ACTION: Notice.
wreier-aviles on DSK5TPTVN1PROD with NOTICES
AGENCY:
In compliance with Section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the Health
Resources and Services Administration
(HRSA) has submitted an Information
Collection Request (ICR) to the Office of
Management and Budget (OMB) for
review and approval. Comments
submitted during the first public review
SUMMARY:
VerDate Mar<15>2010
14:45 Dec 16, 2013
Jkt 232001
57
57
57
Number of
responses per
respondent
Information Collection Request Title:
Evaluation of the Frontier Community
Health Care Network Coordination
Grant
OMB No. 0915–xxxx—NEW.
Abstract: In fiscal year (FY) 2012, the
Office of Rural Health Policy (ORHP)
funded an evaluation of the Frontier
Community Health Care Network
Coordination (FCHCNC) grant. This 3year grant program awarded to the
Montana Department of Public Health
and Human Services focuses on a
community-based, client-centered
clinical service coordination and health
promotion model. The program will be
coordinated by a clinically-trained Care
Transitions Coordinator (CTC) working
with Community Health Workers (CHW)
in 11 participating network
communities. By developing
intervention with clients, the CTC and
CHWs will work to improve care
Frm 00042
Fmt 4703
Total
responses
1
3
........................
of this ICR will be provided to OMB.
OMB will accept further comments from
the public during the review and
approval period.
DATES: Comments on this ICR should be
received within 30 days of this notice.
ADDRESSES: Submit your comments,
including the Information Collection
Request Title, to the desk officer for
HRSA, either by email to OIRA_
submission@omb.eop.gov or by fax to
202–395–5806.
FOR FURTHER INFORMATION CONTACT: To
request a copy of the clearance requests
submitted to OMB for review, email the
HRSA Information Collection Clearance
Officer at paperwork@hrsa.gov or call
(301) 443–1984.
SUPPLEMENTARY INFORMATION:
PO 00000
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this Information
Collection Request are summarized in
the table below.
Total Estimated Annualized burden
hours:
Sfmt 4703
57
171
228
Average
burden per
response
(in hours)
Total burden
hours
3.0
1.5
........................
171.0
256.5
427.5
transitions and client outcomes by
reducing or eliminating avoidable
hospitalizations and re-hospitalizations,
emergency room (ER) visits, and nursing
home placements.
The program will be subject to a 3year independent evaluation. As part of
this 3-year evaluation, HRSA will be
collecting qualitative and quantitative
information. To support the qualitative
analysis, HRSA will conduct site visits
and telephonic key informant
interviews with the critical access
hospitals, tertiary hospitals, and the
support staff coordinating the program.
Data collection will focus on client/
family satisfaction, whether goals were
achieved in working with clients, and
the strengths and challenges associated
with implementing the program.
Additionally, HRSA will be collecting
data quarterly from the grantee sites in
order to gain a deeper understanding of
the program’s implementation. Finally,
quantitative data will be gathered for
studying the effectiveness of each
intervention, specifically identifying
differences between pre- and postintervention health care utilization,
hospital readmissions, and other clientspecific outcomes. Where data are
available, HRSA will assess cost
effectiveness of the program.
Need and Proposed Use of the
Information
This evaluation will consist of
reviewing the implementation and
effectiveness of the FCHCNC grant for
the 11 participating network
communities. The evaluation will allow
HRSA to determine the following
objectives:
E:\FR\FM\17DEN1.SGM
17DEN1
Agencies
[Federal Register Volume 78, Number 242 (Tuesday, December 17, 2013)]
[Notices]
[Pages 76309-76310]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-29991]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Agency Information Collection Activities: Proposed Collection:
Public Comment Request
AGENCY: Health Resources and Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In compliance with the requirement for opportunity for public
comment on proposed data collection projects (Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995), the Health Resources and Services
Administration (HRSA) announces plans to submit an Information
Collection Request (ICR), described below, to the Office of Management
and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks
comments from the public regarding the burden estimate, below, or any
other aspect of the ICR.
DATES: Comments on this Information Collection Request must be received
within 60 days of this notice.
ADDRESSES: Submit your comments to paperwork@hrsa.gov or mail the HRSA
Information Collection Clearance Officer, Room 10-29, Parklawn
Building, 5600 Fishers Lane, Rockville, MD 20857.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the data collection plans and
draft instruments, email paperwork@hrsa.gov or call the HRSA
Information Collection Clearance Officer at (301) 443-1984.
SUPPLEMENTARY INFORMATION: When submitting comments or requesting
information, please include the information request collection title
for reference.
Information Collection Request Title: HRSA AIDS Drug Assistance
Program Quarterly Report OMB No. 0915-0294--Extension
Abstract: HRSA's AIDS Drug Assistance Program (ADAP) is funded
through Part B of Title XXVI of the Public Health Service Act, as
amended by the Ryan White HIV/AIDS Treatment Extension Act of 2009 (The
Ryan White HIV/AIDS Program), which provides grants to states and
territories. ADAP provides medications for the treatment of HIV
disease. Program funds may also be used to purchase health insurance
for eligible clients or for services that enhance access, adherence,
and monitoring of drug treatments.
Need and Proposed Use of the Information: Each of the 50 states,
the District of Columbia, Puerto Rico, the Virgin Islands, and the
Pacific territories receive ADAP grants. As part of the funding
requirements, ADAP grantees submit quarterly reports that include
information on patients served, pharmaceuticals dispensed, pricing,
sources of support to provide HIV/AIDS medications, eligibility
requirements, cost data, and coordination with
[[Page 76310]]
Medicaid. Each quarterly report requests updates from programs on the
number of patients served, type of pharmaceuticals dispensed, and
prices paid to provide medications. The first quarterly report of each
ADAP fiscal year (due in July of each year) also requests information
that only changes annually (e.g., state funding, drug formulary,
eligibility criteria for enrollment, and cost-saving strategies
including coordination with Medicaid).
Describe the need for the information and proposed use of the
information: The quarterly report represents the best method for HRSA
to determine how ADAP grant funds are expended and to provide answers
to requests from Congress and other organizations.
Likely Respondents: ADAP Grantees.
Burden Statement: Burden in this context means the time expended by
persons to generate, maintain, retain, disclose or provide the
information requested. This includes the time needed to review
instructions; to develop, acquire, install and utilize technology and
systems for the purpose of collecting, validating and verifying
information, processing and maintaining information, and disclosing and
providing information; to train personnel and to be able to respond to
a collection of information; to search data sources; to complete and
review the collection of information; and to transmit or otherwise
disclose the information. The total annual burden hours estimated for
this Information Collection Request are summarized in the table below.
Total Estimated Annualized burden hours:
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Form name Number of responses per Total per response Total burden
respondents respondent responses (in hours) hours
----------------------------------------------------------------------------------------------------------------
ADAP Quarterly Report--Qtr. 1... 57 1 57 3.0 171.0
ADAP Quarterly Reports--Qtr. 1, 57 3 171 1.5 256.5
2, & 3.........................
Total....................... 57 .............. 228 .............. 427.5
----------------------------------------------------------------------------------------------------------------
HRSA specifically requests comments on (1) the necessity and
utility of the proposed information collection for the proper
performance of the agency's functions, (2) the accuracy of the
estimated burden, (3) ways to enhance the quality, utility, and clarity
of the information to be collected, and (4) the use of automated
collection techniques or other forms of information technology to
minimize the information collection burden.
Dated: December 9, 2013.
Bahar Niakan,
Director, Division of Policy and Information Coordination.
[FR Doc. 2013-29991 Filed 12-16-13; 8:45 am]
BILLING CODE 4165-15-P